Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
Therapy for Ph-positive chronic myeloid leukemia (CML) with the tyrosine kinase inhibitor imatinib results in achievement of high hematological and cytogenetic response rates. However, most patients with a complete cytogenetic response were found to have a minimal residual disease. Therefore the rol...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/748 |
| _version_ | 1826557081691357184 |
|---|---|
| author | S. I. Kutsev M. V. Velchenko A. N. Zelzer |
| author_facet | S. I. Kutsev M. V. Velchenko A. N. Zelzer |
| author_sort | S. I. Kutsev |
| collection | DOAJ |
| description | Therapy for Ph-positive chronic myeloid leukemia (CML) with the tyrosine kinase inhibitor imatinib results in achievement of high hematological and cytogenetic response rates. However, most patients with a complete cytogenetic response were found to have a minimal residual disease. Therefore the role of molecular monitoring during CML therapy has recently increased. Regular molecular monitoring allows to early diagnosis of relapse and improvement of treatment outcome as a result of therapeutic intervention. For the imatinib-treated patients therapy resistance or increased BCR-ABL gene expression is an indication for kinase domain mutations testing. Detection of the mutations causing imatinib resistance is required for therapy choice. Real-time polymerase chain reaction and DNA sequencing should become customary for CML monitoring. |
| first_indexed | 2024-04-09T20:24:06Z |
| format | Article |
| id | doaj.art-3f37cb8fd54c4260b75226f3ff82e090 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2025-03-14T08:22:56Z |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-3f37cb8fd54c4260b75226f3ff82e0902025-03-02T13:07:15ZrusABV-pressОнкогематология1818-83462413-40232022-11-0104172510.17650/1818-8346-2008-0-4-17-25626Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemiaS. I. Kutsev0M. V. Velchenko1A. N. Zelzer2Rostov State Medical UniversityRostov State Medical UniversityRostov State Medical UniversityTherapy for Ph-positive chronic myeloid leukemia (CML) with the tyrosine kinase inhibitor imatinib results in achievement of high hematological and cytogenetic response rates. However, most patients with a complete cytogenetic response were found to have a minimal residual disease. Therefore the role of molecular monitoring during CML therapy has recently increased. Regular molecular monitoring allows to early diagnosis of relapse and improvement of treatment outcome as a result of therapeutic intervention. For the imatinib-treated patients therapy resistance or increased BCR-ABL gene expression is an indication for kinase domain mutations testing. Detection of the mutations causing imatinib resistance is required for therapy choice. Real-time polymerase chain reaction and DNA sequencing should become customary for CML monitoring.https://oncohematology.abvpress.ru/ongm/article/view/748chronic myeloid leukemiabcr-abl gene expressionmutations of bcr-abl gene kinase domaintyrosine kinase inhibitors |
| spellingShingle | S. I. Kutsev M. V. Velchenko A. N. Zelzer Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia Онкогематология chronic myeloid leukemia bcr-abl gene expression mutations of bcr-abl gene kinase domain tyrosine kinase inhibitors |
| title | Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia |
| title_full | Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia |
| title_fullStr | Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia |
| title_full_unstemmed | Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia |
| title_short | Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia |
| title_sort | molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia |
| topic | chronic myeloid leukemia bcr-abl gene expression mutations of bcr-abl gene kinase domain tyrosine kinase inhibitors |
| url | https://oncohematology.abvpress.ru/ongm/article/view/748 |
| work_keys_str_mv | AT sikutsev moleculargeneticsmonitoringoftyrosinekinaseinhibitortherapyforchronicmyeloidleukemia AT mvvelchenko moleculargeneticsmonitoringoftyrosinekinaseinhibitortherapyforchronicmyeloidleukemia AT anzelzer moleculargeneticsmonitoringoftyrosinekinaseinhibitortherapyforchronicmyeloidleukemia |